GlaxoSmithKline: Dolutegravir (whose brand name will be Tivicay) approved by the FDA

NEUTRAL, Fair Value  1900p (+14%)

News published on August Tuesday 13, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities